RCS - SkinBioTherapeutics - Zenakine™ Technical Presentation & Share Price

SkinbiotherapeuticsAnnouncement

09/04/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250409:nRSI2145Ea&default-theme=true

RNS Number : 2145E  SkinBioTherapeutics PLC  09 April 2025

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

 

Successful technical presentation of Zenakine™ by Croda Beauty team

 

Comment on reduction in share price

 

·    Croda holds technical presentation at the in-cosmetics global 2025
meeting to full capacity auditorium and receives standing ovation

·    Zenakine™ additional benefits revealed at the launch, including
 improvement of cell longevity and skin regeneration for increased
anti-ageing

·    Management sees no reason behind movement in share price

 

9 April 2025 - SkinBioTherapeutics plc (AIM: SBTX), a life science company
focused on skin health, announces that, following the successful global launch
of Zenakine(TM) by Croda Beauty at the in-cosmetics Global 2025 meeting in
Amsterdam yesterday, management sees no reason for the reduction in share
price on 8 April 2025.

Stuart Ashman, CEO of SkinBioTherapeutics said: "The Croda Beauty team held a
technical presentation to a completely full auditorium (standing room only)
and presented on the cosmetic active ingredient and its benefits - as we had
expected and so much more. The positive reception from the audience was very
exciting to see."

Apart from the anticipated cosmetic claims that the management of
SkinBioTherapeutics had been expecting, Croda Beauty team described additional
biological mechanisms demonstrated by Zenakine(TM):

·      Reduction of cortisol damage via melatonin production to promote
better sleep

·      Resynchronisation of the peripheral skin biological clock to
improve circadian rhythm

·      Improvement of cell longevity and skin regeneration for increased
anti-ageing

·    Reduction of residual tension improving skin regeneration and avoiding
the appearance of expression wrinkles

The presentation received a standing ovation from the audience and the Croda
Beauty stand subsequently received considerable interest in the product. The
SkinBioTherapeutics team looks forward to this interest continuing for the
remainder of the show.

SkinBioTherapeutics' CEO, Stuart Ashman and Dr. Surinder Chahal will discuss
the additional and significant attributes of this extraordinary product, its
applications and commercialisation at the forthcoming Investor Meets Company
Presentation on Wednesday 16th April 2025.

 

-Ends-

SkinBiotix launch presentation webinar

The management team will hold an Investor Meet Company presentation at 11am
BST on 16 April 2025. At this presentation, the team will update
shareholders on both the HY results and the launch.

The presentation will be open to all existing and potential
SkinBioTherapeutics shareholders. Questions can be submitted pre-event via
the Investor Meet Company dashboard
(https://www.investormeetcompany.com/companies/skinbiotherapeutics-plc)  up
until 15 April 2025, 09.00am BST, or at any time during the live
presentation. Investors who already follow SkinBioTherapeutics plc on the
Investor Meet Company platform will automatically be invited.

Investors who already follow SkinBioTherapeutics on the Investor Meet
Company platform will automatically be invited. Investors can sign up
to Investor Meet Company for free HERE
(https://www.investormeetcompany.com/) .

 

For more information please contact:

 

 SkinBioTherapeutics plc                            +44 (0) 191 495 7325

 Stuart J. Ashman, CEO

 Manprit Randhawa, CFO

 Cavendish Capital Markets Limited                  +44 (0) 20 7220 0500

 (Nominated Adviser & Broker)

 Giles Balleny, Dan Hodkinson (Corporate Finance)

 Charlie Combe (Broking)

 Dale Bellis, Tamar Cranford-Smith (Sales)

 Vigo Consulting (financial press)                  +44 (0) 20 7390 0230

 Rozi Morris                                        SkinBio@vigoconsulting.com

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Group's proprietary platform technology, SkinBiotix®, is based upon
discoveries made by the translational dermatology team at the University of
Manchester.

The Group's foundation business is targeting the skin healthcare market via
five pillars, the most advanced of which are cosmetic skincare (SkinBiotix)
and food supplements to modulate the immune system by harnessing the gut-skin
axis (AxisBiotix). The cosmetic pillar has a partnership with Croda plc and
the Group's first in-house product, AxisBiotix-Ps™, is a food supplement to
address the symptoms of mild to moderate psoriasis.

The Group is also acting as a consolidator and is making acquisitions in
complementary areas such as skin care and cosmetic applications, that also
bring new distribution and geographical platforms, and manufacturing
capabilities through which it can funnel its in-house pillar products.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For
more information, visit: www.skinbiotherapeutics.com
(http://www.skinbiotherapeutics.com) .

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAKZGGDMRFGKZZ